Physician profile
Patrick Jenkinson
NPI 1871114348
$657.73
in general payments reported to CMS, 2019-2025
14 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.94 · 2023: $102 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $171.64 | 2025 | Tarpeyo |
| Amgen INC. | $74.81 | 2023-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.86 | 2023-2025 | Jardiance, Ofev |
| Genentech USA, INC. | $60.92 | 2025 | Gazyva |
| Otsuka America Pharmaceutical, INC. | $49.12 | 2025 | Voyxact, Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $45.99 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $41.47 | 2025 | |
| Xeris Pharmaceuticals, INC. | $25.24 | 2025 | Keveyis |
| Alnylam Pharmaceuticals INC. | $24.72 | 2025 | Oxlumo |
| Abbvie INC. | $23.87 | 2023 | |
| Novo Nordisk INC | $22.48 | 2025 | Wegovy |
| Medtronic, INC. | $21.70 | 2023 | Inpen Smart Insulin Delivery System |
| Aurinia Pharma U.S., INC. | $17.24 | 2023 | Lupkynis |
| Ani Pharmaceuticals, INC. | $13.67 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Jenkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.